Loxo Oncology works closely with our strategic partner Array BioPharma (NASDAQ:ARRY). Over many years, and in collaboration with many premier partners, Array BioPharma has developed a chemistry platform uniquely suited to the discovery of highly selective medicines targeting certain oncogenic drivers in cancer. Array BioPharma’s expertise allows us to develop medicines in a very time-efficient process with a high-probability of success.
Our collaboration with Array BioPharma began in July 2013 when we signed a multi-year strategic license and collaboration agreement covering numerous potential drug programs. Array BioPharma handles early stage research, while Loxo Oncology manages clinical, regulatory and commercial execution. Array’s proprietary chemistry library and experienced team provide a world-class drug discovery solution that fits with our goal of precision cancer medicine development. We have unrestricted worldwide commercial rights to each program we develop with Array. In addition to ongoing funding support from Loxo Oncology, Array is eligible to receive potential milestones and royalties contingent on the success of our programs.
Through our partnership with Array BioPharma, we are building highly selective and potent inhibitors against many of the known genetic drivers of cancer. Array’s commitment to drug selectivity and pharmacology is the perfect counterpoint to our search for oncogenic driver cancer targets with unmet clinical need. Selective drugs from Array give us the best chance for optimal doses in patients that, hopefully, translate into safe and durable cancer disease control.